Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Recruiting

Phase 1

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Sponsor:

Institut de Recherches Internationales Servier

Code:

NCT05484622

Conditions

Astrocytoma

Oligodendroglioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vorasidenib

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-08. This information was provided to ClinicalTrials.gov by Institut de Recherches Internationales Servier on 2025-01-14.